54954-12-0

54954-12-0 structure

Name: norswertianolin
Chemical Name: norswertianolin
CAS Number: 54954-12-0
Molecular Formula: C₁₉H₁₈O₁₁
Molecular Weight: 422.340
Catalog: Research Areas Cardiovascular Disease
Create Date: 2017-08-18 16:19:10
Modify Date: 2024-01-08 12:39:03
Norswertianolin acts as a CSE activator and is isolated from G. acuta. Norswertianolin may be a potential agent for cardiovascular diseases[1][2].

Name	norswertianolin
Synonyms	4,6,8-Trihydroxy-9-oxo-9H-xanthen-1-yl β-D-glucopyranoside 9H-Xanthen-9-one, 8-(β-D-glucopyranosyloxy)-1,3,5-trihydroxy-

Description	Norswertianolin acts as a CSE activator and is isolated from G. acuta. Norswertianolin may be a potential agent for cardiovascular diseases[1][2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Others >> Others
Target	CSE[2]
In Vitro	Norswertianolin (3.125~50 μM; H9c2 cells) has the protective effects on H2O2-induced H9c2 cells. Norswertianolin significantly increases the transcription levels of HO-1 and GCLC in H9c2 cells[1]. Norswertianolin (0~150 μM; HepG2 cells) high concentration increases the CSE protein level[2].
In Vivo	Norswertianolin (4.4 mg/kg/day; s.c.; 1 week) improves CSE/H2S production[2]. Norswertianolin treatment attenuates the renal tubular injury in acute I/R. Norswertianolin also reduces I/R-stimulated ROS by DHE fluorescence intensity. Norswertianolin has anti-hypertension effects, inhibits vascular remodeling and reduces inflammation effects[2]. Animal Model: Male Sprague Dawley rats (10~12 weeks)[2] Dosage: 4.4 mg/kg/day Administration: S.c. Result: Improved CSE/H2S production.
References	[1]. Ren K, et al. Effects of Four Compounds from Gentianella acuta (Michx.) Hulten on Hydrogen Peroxide-Induced Injury in H9c2 Cells. Biomed Res Int. 2019;2019:2692970. Published 2019 Jan 20. [2]. Niu Y, et al. Norswertianolin Promotes Cystathionine γ-Lyase Activity and Attenuates Renal Ischemia/Reperfusion Injury and Hypertension. Front Pharmacol. 2021;12:677212. Published 2021 Jul 14. doi:10.3389/fphar.2021.677212